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Abstract
Background: To evaluate, in an initial way, the effectiveness of bioadhesive chlorhexidine gel 0.2% versus placebo 
as a preventive and therapeutic intervention of oral mucositis induced by radiation therapy and chemotherapy in 
patients diagnosed with head and neck cancer treated with chemoradiotherapy.
Material and Methods: �n this pilot study, 7 patients (range of age: 18- 65), having histological documented diag-
nosis of squamous carcinoma on the head and neck region in stage ��� and �V, and receiving combined radiation 
treatment and chemotherapy (cisplatin 100 mg/m2 �V on days 1, 22, and 43 of irradiation) were studied. Simul-
taneously, a topical application was performed with bioadhesive chlorhexidine gel 0.2% in the study group, and 
the placebo gel for the control group in 5 applications per day, from the time of initiation of cancer treatment to 
2 weeks after completion of chemo-radiotherapy treatment (11 weeks of follow-up). The gradation of mucositis, 
pain, analgesic consumption, infectious complications, and treatment tolerance was measured.
Results: After 7 patients completed the protocol, any differences were observed between groups in an interval 
analysis. Mucositis, pain, and tolerance was similar in both groups.
Conclusions: Our results must be interpreted with caution due to the reduced sample size, but the use of bioad-
hesive chlorhexidine gel 0.2% didn’t contribute clinical improvement to the oral mucositis induced by radiation 
therapy and chemotherapy. 
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Introdution
Oral mucositis (OM) is considered one of the major de-
bilitating side effects of cancer therapy due to the di-
rect radiation of the mucosa with radiotherapy or by the 
effect of chemotherapy (1,2). This illness is described 
as the result of inflammation changes in the epithelial 
and sub-epithelial cells irradiated or affected by the 
treatment, causing discomfort in the patients because of 
the generalized erythema, frank ulceration, and denu-
dation, associated with local pain as well, which cons-
titutes the most important clinical manifestations of 
oropharyngeal mucositis (1,3). The induced pain makes 
it difficult for patients to eat, swallow, speak, or perform 
oral hygiene measures. These effects result in weight 
loss, dehydration, and a risk of oral infections (1).
Today, radiotherapy (RT) and chemotherapy (QT) cons-
titute as one of the most commonly used combinations 
of therapies for head and neck cancer (H&NC). �t has 
been demonstrated in previous studies that the associa-
tion of these types of treatments result more effectively 
than using radiotherapy alone. Actually, the most fre-
quent treatment is the programmed sessions of QRT, 
being necessary in most cases of surgical intervention 
too. The treatment must be uninterrupted; it has been 
demonstrated that the proliferation risk of residual tu-
mor cells is incremented when the radiotherapy or the 
programmed chemotherapy is abandoned or interrup-
ted, causing recurrences of the tumor and affecting the 
life quality of the patient (4).
Ninety percent of patients with head and neck cancer re-
ceiving standard radiotherapy and chemoradiotherapy 
will develop oropharyngeal mucositis (3), varying the 
incidence according to the oncology treatment schedule 
(5).
�ntraoral lesions are commonly localized in non-que-
ratinized oral mucosa, such as lip and buccal mucosa, 
lateral and anterior mucosa of the tongue, floor of the 
mouth, and soft palate. The hard palate and gums seem 
to be less susceptible to the effects of chemotherapy and 
radiotherapy (6).
In a conventional radiotherapy, the first radiation dose 
(10 Gy) causes a hiperqueratinized lesion, where a whi-
tish appearance can go unnoticed. An early sign of OM 
includes erythema, which appears after approximately 
20 Gy of cumulative radiation dosage for head and neck 
tumors. After 7–10 days, or a cumulative dosage of 30 
Gy, ulcers covered by a pseudomembrane are detected; 
these pseudomembranes bring on the bacterial coloni-
zation with a high risk of sobreinfection, which are as-
sociated with discomfort and changes in patient dietary 
habits. Radio-induced OM lasts for at least 2 to 6 weeks 
after radiation therapy has finished (7,8).
OM induced by chemotherapy is usually more aggres-
sive than that caused by radiotherapy. After 5-8 days 
of treatment, erythema appears, and 2 days after, edema 
and ulceration can be observed (7). Erythema is obser-
ved around the fifth–eighth day of treatment, and in the 
following days, edema and ulceration can be observed. 
After the end of the chemotherapy treatment, the mucosa 
will need about 7-10 days to recover completely (7). 
Nowadays, there are a large number of treatments that we 
can choose from, but the strategies to reduce oral muco-
sitis are still unclear. Due to the importance of the OM, 
many studies have been carried out. Different techniques 
have been described like intensive oral care protocol, 
antimicrobial agents, antiinflammatory agents, citopro-
tectors agents, nutritional supplements, bioestimulants 
agents, or natural and homeopathic agents. Although all 
of these treatment options exist (6,9-11) to prevent and 
treat mucositis, there is no gold-standard protocol that 
is prominently better than the rest because there is not 
enough evidence describing a treatment with proven effi-
ciency to surpass the other treatments for this condition 
(6,9,12-14). 
Chlorhexidine is approved for use as an antibacterial 
mouthwash at a concentration of 0.12% and 0.2% to pre-
vent the build-up of dental plaque and to prevent gingi-
vitis (9,15). �ts broad spectrum of antibacterial activity, 
minimal systemic absorption, and ability to bind to oral 
surfaces led to the use of prophylaxis in an attempt to pre-
vent the development of oral mucositis (16). However, it 
has some disadvantages such as the discoloration of tee-
th, the bitter taste, and the unpleasant sensation (17,18). 
The aim of this pilot study was to evaluate, in an ini-
tial way, the effectiveness of bioadhesive chlorhexidine 
gel 0.2% versus placebo as a preventive and therapeutic 
intervention of oral mucositis induced by radiation the-
rapy and chemotherapy in patients diagnosed with head 
and neck cancer treated with chemoradiotherapy.
Material and Methods
- Patient Characteristics and place of study
The pilot study was conducted in the oncology de-
partment of the University Hospital “Virgen del Rocío” 
in Seville after approval from the local �nternal Review 
Board. This was a prospective, placebo-controlled, ran-
domized, and double-blind pilot study.
The inclusion criteria was the following: patients aged 
18-65, who had histological documented diagnosis of 
squamous carcinoma on the head and neck region in 
stage III and IV according to the TNM classification 
and who received combined radiation treatment (con-
ventional fractionation 70 Gy reaching the tumor and 
affected lymph nodes, and 50 Gy at the nodal areas dra-
inage in 9 weeks) and chemotherapy (cisplatin 100 mg/
m2 �V on days 1, 22, and 43 of irradiation). The patients 
voluntarily expressed their intention to participate in 
the clinical trial with informed consent before enrolling 
in the study.
The exclusion criteria was the following: patients who 
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have hypersensitivity or an allergy to any of the compo-
nents included in the study, patients with H�V, diabetes 
and autoimmune diseases, and those who do not fulfill 
all of the inclusion criteria mentioned above.
After carrying out this pilot study, 7 registered patients, 
4 in the study group, and 3 in the control group, the study 
was stopped. All the patients fulfilled the pilot study.
- Study groups 
Experimental/study group: �n the protocol of treatment, 
these patients performed topical application with bio-
adhesive chlorhexidine gel 0.2%. �n the control group, 
these patients used a placebo gel in the way that we spe-
cify below.  
- Study design
The study protocol consisted of the administration of a 
multivitamin that contained vitamin E and Zinc Sulfate, 
the performance of rinses with 15 ml of Benzydamine 
for 2 minutes, 5 times a day, and the local application of 
ice on the oral mucosa at least for 20 minutes on days 1, 
22, and 43 of cancer treatment (after chemotherapy with 
cisplatin), besides the application of radiotherapy for 9 
weeks (exposed previously). 
Simultaneously,  topical application was performed with 
bioadhesive chlorhexidine gel 0.2% in the study group 
and placebo gel for the control group in 5 applications 
per day from the time of initiation of cancer treatment 
to 2 weeks after completion of chemo-radiotherapy 
treatment (total time of study was 77 days, 11 weeks). 
The patient was instructed in the placement of the gel 
(placebo or chlorhexidine) with a syringe by extracting 
a dose of 10 ml for each application, 5 times per day, 
after rinsing with benzydamine.
The randomization and double-blind trial was carried 
out as follows. Both gels were prepared by LACER la-
boratories in Barcelona (Spain). The needed hardware 
was added for all samples to have identical color, flavor, 
and texture, which in turn would be comfortable for the 
patient. Patients were randomly assigned to receive ei-
ther protocol of oral care with chlorhexidine or placebo 
by selection of a sealed envelope (randomized list gene-
rated by computer).
The patient scored daily in a booklet provided below for 
the onset of pain and its intensity before applying the 
gel, immediately after, and 3 hours later (using a visual 
analog scale numbered from 0 to 100) in the first appli-
cation of the gel during the day. �t was also noted in this 
booklet if the use of analgesics and/or anti-inflamma-
tory oral mucositis was required, and in what quantity 
(number of pills and doses).
The study was planned and carried out in compliance 
with the Declaration of Helsinki and Good Clinical 
Practice. The pilot study protocol was approved by the 
Experimentation Ethics Committee (EC) of the Univer-
sity of Seville and financed by the Andalusian Health 
Service (Code S�G�- S0095). 
- Clinical assessment protocol
Gradation, occurrence, and remission of mucositis
The integrity of the mucosa was assessed using the 
WHO criteria for the grading of oral mucositis on a 
scale of 0–4, where 0 is “no change,” 1 corresponds 
to “erythema and/or pain,” 2 “ulceration and ability to 
eat,” 3 “ulceration and limited ability to eat,” and 4 “ul-
ceration with hemorrhage and necrosis.” The examiner 
is always the same to avoid the variability between di-
fferent examiners’ criteria.
�nitial exploration of the oral mucosa is recorded before 
the beginning of chemo-radiotherapy, and subsequent 
reviews were carried out weekly until 2 weeks after the 
full cancer treatment of the patients.
- Pain
Patients rated pain sensation following a visual analo-
gue scale (VAS) flat with values  ranging from 0 (“no 
pain”) and the value 100 (“unbearable pain”). This an-
notation was made at home once a day throughout the 
study, before applying the gel, immediately after, and 3 
hours after (first daily gel application).
- Adjuvant analgesics
Patients recorded in the same booklet if they took anal-
gesics or anti-inflammatories due to mucositis, and they 
specified the amount of drugs required on a daily basis.
- Treatment tolerance
The evaluation of tolerance was based on the frequency 
with which patients have had at least one adverse event 
during the trial. The patient and investigator will score 
the global tolerance at the end of treatment by an oral 
5-point scale: 5 = very good, 4 = good, 3 = moderate, 2 
= poor, and 1 = very poor. 
- �nfectious complications
The investigator assessed the occurrence of complica-
tions due to infection of the lesions of  mucositis in wee-
kly reviews during treatment.
- Data analysis
Data were analyzed using SPSS 9 for Windows Support 
Unit Research Hospital Universitario “Virgen del Ro-
cio.” We used the chi-square test for the analysis of the 
data obtained in the comparison of qualitative variables 
and Mann–Whitney U test for comparison of means.
Results
�n this pilot study, 7 patients with head and neck carci-
noma treated with chemo-radiotherapy were randomi-
zed and included in the intention-to-treat population for 
efficacy analyses. The patients consisted of 5 men and 
2 women with mean age of 59.57 ± 10.97 years. �n the 
control group, 3 patients were treated with a mean age 
of 63.3 ± 15.89 years. �n the experimental group, 4 pa-
tients were treated with an average age of 56.75 ± 6.90 
years (Table 1). All patients were undergoing treatment 
chemo-radiotherapy.
Regarding the frequency of the hygienic habits, 4 pa-
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tients had a frequency of 3 times per day, 2 patients 2 
times per day, and 1 of them 1 time per day. However, 
in terms of harmful habits, only 2 patients had no such 
habit, 2 of them were ex-smokers, 2 were smokers and 
drinkers, and one of them was a drinker (Table 2).
The integrity of the mucosa to the WHO scale for mu-
cositis was slightly higher in the study group than in the 
control group, but without obtaining statistically signi-
ficant differences (p>0.05) (Table 3).
�n relation to the pain associated with the application 
of gel, a greater degree of pain prior to placement in 
the study group than in the control group was observed 
(Fig. 1), although the pain at the time of gel applica-
tion and 1 hour later of placement was less in the study 
group versus the control group (Figs. 2,3). However, no 
differences in trends were found between the chlorhexi-
dine and placebo. 
The tolerance of the treatment from the patients’ and 
researchers’ point of view had the same punctuation on 
the scale from 1 to 5. �n the study group, the tolerance 
was slightly better than in the control group (Table 4). 
Moreover, infectious complications were similar in the 
experimental group than in the control group (Table 5). 
No statistically significant differences were found in 
any of the two variables (p>0.05).
Table 1. Characteristics of the patients included in the study.
 AGE (years) SEX TOTAL OF PATIENTSMen Women 
CHX 0,2% 56.75 ± 6.90 3 1 4 
Placebo 63.33 ± 15.89 2 1 3 
Total 59.57 ± 10.97 5 2 7 
 
SMOKING HABIT HYGIENIC HABIT 
No 
Smoker 
10-20 
cigarettes 
 20 
cigarettes 
Ex-
Smoker Total 
1 Teeth 
brushing 
2 Teeth 
brushing 
3 Teeth 
brushing Total 
CHX 
0,2% 1 1 0 2 4 0 2 2 4 
Placebo 1 1 1 0 3 1 0 2 3 
Total 2 2 1 2 7 1 2 4 7 
Table 2. Habits of the patients included in the study.
Table 3.  The integrity of the mucosa to the WHO scale for Mucositis along the study.
 CHX 0,2% Placebo 
Significance
 1 2 3 4 5 1 2 3 4 5 
1 Week 4(100%) 0(0%) 0(0%) 0(0%) 0(0%) 3(100%) 0(0%) 0(0%) 0(0%) 0(0%) 0.999 
2 Week 2(50%) 1(25%) 1(25%) 0(0%) 0(0%) 3(100%) 0(0%) 0(0%) 0(0%) 0(0%) 0.350 
3 Week 0(0%) 2(50%) 0(0%) 2(50%) 0(0%) 1(33%) 1(33%) 1(33%) 0(0%) 0(0%) 0.233 
4 Week 0(0%) 1(25%) 0(0%) 3(75%) 0(0%) 0(0%) 3(100%) 0(0%) 0(0%) 0(0%) 0.030 
5 Week 0(0%) 1(25%) 1(25%) 1(25%) 1(25%) 0(0%) 0(0%) 3(100%) 0(0%) 0(0%) 0.268 
6 Week 0(0%) 1(25%) 1(25%) 1(25%) 1(25%) 0(0%) 0(0%) 0(0%) 3(100%) 0(0%) 0.268 
7 Week 0(0%) 1(25%) 1(25%) 1(25%) 1(25%) 0(0%) 0(0%) 0(0%) 3(100%) 0(0%) 0.268 
8 Week 1(25%) 0(0%) 1(25%) 1(25%) 1(25%) 0(0%) 0(0%) 0(0%) 3(100%) 0(0%) 0.268 
9 Week 1(25%) 0(0%) 2(50%) 0(0%) 1(25%) 0(0%) 0(0%) 0(0%) 3(100%) 0(0%) 0.072 
10 Week 0(0%) 1(25%) 1(25%) 1(25%) 1(25%) 0(0%) 0(0%) 0(0%) 3(100%) 0(0%) 0.268 
11 Week 1(25%) 0(0%) 2(50%) 0(0%) 1(25%) 0(0%) 3(100%) 0(0%) 0(0%) 0(0%) 0.072 
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Fig. 1. Pain prior to placement the gel in the study group than in the control group.
Fig. 2. Pain at the time of gel application.
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Discussion
This is a report of a pilot study. The calculations of the 
sample that were necessary to extrapolate the data once 
they were drawn from the study sample were carried 
out and the total number of patients was calculated as 
96. However, the authors have decided not to advance in 
this final study. The reasons for this included the very 
limited effectiveness (if some are present) of the drug 
used in the study group (chlorhexidine gel 0.2%) com-
pared to placebo.
Data from several randomized clinical trials show that 
chlorhexidine rinses do not have a major impact on the 
prevention of mucositis in patients undergoing radiothe-
rapy (18,19). However, it significantly seems to reduce 
oral inflammation and ulceration in patients undergoing 
chemotherapy. Chlorhexidine rinses are treatments that 
are applied across the surface of the oral cavity without 
acting specifically on lesions, so the use of chlorhexidi-
ne gel would seem to have a more advantageous indi-
cation for the treatment of injuries caused by mucositis 
because of the localized application (20). 
�n opposition to the initial hypothesis, our results don’t 
show a clinical improvement of the study group’s pa-
tients. The use of bioadhesive chlorhexidine gel 0.2% 
does not reduce the frequency of mucositis in the oral 
cavity or the pain caused by mucositis induced by can-
cer treatment, and with no significant differences bet-
ween the patients’ pain before and after the application 
of it. These results are in agreement with other  work 
with chlorhexidine rinse, as in the paper presented by 
Rutkauskas and David (21), who investigated the effect 
of chlorhexidine versus a placebo in patients under-
Fig. 3. Pain one hour after the application.
 Patient Observation  Researcher Observation 
 1 2 3 4 5 Significance 1 2 3 4 5 Significance 
CHX 0,2% 0 1 2 1 0 0.646 0 1 2 1 0 0.646 Placebo 0 0 2 1 0 0 0 2 1 0 
Table 4. Tolerance of the treatment from the Patient and the Researcher View.
INFECTIOUS 
COMPLICATION 
NO INFECTIOUS 
COMPLICATION Significance
CHX 0,2% 2 (50%) 2 (50%) 0.659 Placebo 2 (66%) 1 (33%) 
Table 5. �nfectious Complication on the study and control group.
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going haematopoietic stem cell transplant (HSCT) or 
remission-indication chemotherapy. The study showed 
chlorhexidine to be ineffective in preventing mucositis. 
Also, Raether and colleagues did not support the use of 
chlorhexidine mouthwash for the prevention of muco-
sitis in patients with bone marrow transplantation, and 
they found that there was no significant difference in 
the severity of oral ulceration between the chlorhexidi-
ne and placebo groups (22-24). However, there are stu-
dies that support prophylactic use of 0.12% chlorhexidi-
ne gluconate to reduce the frequency of oral mucositis 
and oral pathogens in children with Acute Lymphoblas-
tic Leukemia undergoing antineoplastic chemotherapy 
(25,26). The preventive oral protocol using chlorhexi-
dine mouthwash can reduce both the incidence and the 
severity of oral lesions in children suffering from leuke-
mia receiving chemotherapy, according to these studies 
(25). 
Nevertheless, it can be suggested from the data pre-
sented here that chlorhexidine may play a part in redu-
cing oral damage during radio-chemotherapy, possibly 
through plaque control and a reduction in the oral mi-
croflora (26,27). There was no difference in mucositis 
between the groups although bacterial and fungal infec-
tions were found slightly less often among the patients 
using chlorhexidine. However, it cannot be translated 
into a reduction in the pain produced by mucositis. The-
se results are in accordance with those published with 
chlorhexidine mouthwash (21). 
Nowadays, numerous studies can be found about the 
treatment or the prevention of the mucositis with diffe-
rent products. Chlorhexidine mouthwash is a common 
product tested in the treatment of this illness, and not 
only in comparison with the placebo. Dodd et al. pu-
blished some studies in which chlorhexidine was com-
pared with sterile water (28) and another study in which 
a solution of Lidocaine, Benadryl, and Maalox (29) was 
the object of comparison. No differences in the severity 
of mucositis were found between the groups in those 
studies. However, there was a decrease in the number of 
microorganisms in the CHX groups compared with the 
control groups (30). 
Chlorhexidine has been also compared with benzyda-
mine hydrochloride oral rinses for the prevention and 
treatment of irradiation mucositis in patients with head 
and neck cancer (3). Significant differences were not de-
tected between groups on outcome measures; a trend has 
emerged toward a lessening of oropharyngeal mucosi-
tis for patients who received benzydamine compared to 
patients who received chlorhexidine (3). However, these 
results contrast with those published by Cheng, who sta-
ted that from the patients’ perspective, chlorhexidine is 
more helpful than benzydamine in reducing mucositis 
and palliating oral discomfort (31).
Other products have been tested for the prevention 
and treatment of oral mucositis like zinc-containing 
mouthwash (25) or amine-stannous fluoride solution 
(32). None of these rinses have shown clear advantages 
over chlorhexidine so there is still no treatment for this 
complication of the treatment of head and neck cancer.
Currently, there is no effective therapy to resolve or 
substantially improve the symptoms of mucositis al-
ready established (9), although recent studies show that 
the use of a low energy laser can be a promising therapy 
(33,34). 
�t should be pointed out that the results of the present 
pilot study should be interpreted with caution due to 
the reduced sample size. Nevertheless, it seems that in 
agreement with the evidence indicating that chlorhexi-
dine rinse is not useful for the prevention and treatment 
of the mucositis induced by chemoradiotherapy of head 
and neck cancer (27,30), the application of gel bioadhe-
sive of chlorhexidine with the same intention has the 
same usefulness.
In our opinion, further studies will be required to find a 
treatment different from the chlorhexidine (rinse or gel) 
for mucositis and improve the quality of life of patients 
undergoing chemoradiotherapy.
Conclusions 
�n this double-blind, randomized pilot study, the gel bio-
adhesive of chlorhexidine 0.2% has not provided better 
clinical results than a placebo on pain and discomfort in 
the oral mucositis caused by chemoradiotherapy in the 
treatment of head and neck cancer.  
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